Navigation Links
OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
Date:9/6/2011

tify opportunities to block these mechanisms in order to delay tumor progression."

The abstract can be found at the following link:

http://cancerres.aacrjournals.org/content/71/17/5838.abstract

About Custirsen

Custirsen is the only compound currently in development designed to inhibit the production of clusterin, a protein commonly over-produced in cancer cells, and one cause of treatment resistance. Unlike opioids or agents that target the androgen receptor, custirsen is mechanistically unique in its ability to impact pain responses via the regulation of NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) activity.  This is a potential attribute that could contribute to custirsen's clinical benefit in combination with numerous anti-cancer treatments.

Custirsen has received Fast Track designation from the U.S. Food and Drug Administration (FDA).

More information is available at www.OncoGenex.com and www.tevapharm.com/research.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NASDAQ:  TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase III clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase III development of custi
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
2. OncoGenex Reports Third Quarter Financial Results
3. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
5. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
6. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
7. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
8. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
9. OncoGenex Reports Second Quarter Financial Results
10. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
11. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Global Resorcinol Market 2015-2019 is ... on the global resorcinol industry. The report highlights the various growth prospects and ... and analysis of primary and secondary inputs from the existing players of the ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... detection and quantification of partially hydrolyzed gluten in foods, has been accepted by ... the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” ...
(Date:7/30/2015)... , July 30, 2015 AACC welcomed ... the 2015 AACC Annual Meeting & Clinical Lab ... July 26–30. The meeting showcased revolutionary advancements in ... ability of healthcare providers to diagnose patients quickly ... medical treatment. As of Wednesday, ...
(Date:7/30/2015)... France and Dallas, TX, USA (PRWEB) , ... ... ... of innovative nano and microsystems, has appointed Francois Vieillard as Sales & Marketing ... Marketing at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2
... 7 Codexis, Inc. today announced,a licensing agreement with ... product, using a proprietary Codexis,biocatalyst. Teva, the largest ... of this generic product. The product is one ... States. , Under the agreement, ...
... Calif., Jan. 7 Intradigm Corporation, a leading,developer ... that the company has closed the final tranche ... the $2.9 million tranche, with,existing investor, Lilly Ventures, ... the total Series B financing to $21.4 million. ...
... Abaxis, Inc. (Nasdaq: ABAX ), a ... for both the medical and veterinary markets, announced ... agreement for co-exclusive worldwide rights in the field ... for certain technologies pertaining to lateral flow immunoassay ...
Cached Biology Technology:Codexis, Teva in Licensing Agreement Final 2Intradigm Closes Final Tranche of $21.4 Million Series B Financing 2Intradigm Closes Final Tranche of $21.4 Million Series B Financing 3ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology 2ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology 3
(Date:7/23/2015)... Aware, Inc. (NASDAQ: AWRE ), a leading ... for its second quarter ended June 30, 2015.  ... million, a decrease of 33% compared to $6.8 million in ... quarter of 2015 was $0.3 million, or $0.01 per diluted ... share, in the same period a year ago.  ...
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, ... expected revenues in 2015 that relate to sales of FPC1025 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... in China and we are proud that ... for Axon , its first ...
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... skull-splitting pain. Scientists have found evidence that the headaches ... parts of the brain starved for oxygen and altering ... the work by neuroscientists at the University of Rochester ... , The scientists say the work makes it ...
... new study appearing in the May issue of The ... geologists must account for when examining dinosaur tracks. The ... family of dinosaurs that includes the T. Rex and ... effects of many different types of erosion on these ...
... more than just making pie, according to new data from ... researchers and presented today at a major scientific meeting. ... animals that received powdered tart cherries in their diet had ... the liver, lower oxidative stress and increased production of a ...
Cached Biology News:Mice with a migraine show signs of brain damage 2Mice with a migraine show signs of brain damage 3Mice with a migraine show signs of brain damage 4Mice with a migraine show signs of brain damage 5How to look at dinosaur tracks 2A cherry on top: Tart cherries may alter heart/diabetes factors 2A cherry on top: Tart cherries may alter heart/diabetes factors 3A cherry on top: Tart cherries may alter heart/diabetes factors 4
... Caliper's iLink makes it easy to supply ... instruments. Developed with operator convenience in mind, ... shoot' ease of use. The iLink software ... for assays or sub-assays, that can be ...
... As research demands continue to grow, ... more spectral information has become necessary, especially ... spectral colors. The innovative C1si Confocal Microscope ... speed and spectral capability not available in ...
... LAS-3000 imaging system combines new CCD ... interface, providing significantly improved system sensitivity ... The LAS-3000 provides significantly improved system ... applications including: fluorescence, chemifluorescence, chemiluminescence, and ...
The LAS-3000 imaging system combines new CCD camera technology with a simplified user interface to provide significantly improved system sensitivity with a wide range of modularities. This system is...
Biology Products: